Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEC Chemotherapy Plus Androgen Ablation and Radiation for Localized Prostate Cancer
NCT00016913Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- May 2001
- Primary completion
- Jul 2007
- Modality
- DNA Intercalators/Alkylators, Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Paclitaxel Micelles for Injection, estramustine and carboplatin in prostate cancer (PCa), sponsored by Cancer and Leukemia Group B. Primary endpoint: Toxicity at 1 year. Started May 2001; status: completed.
02
Drugs
Paclitaxel Micelles for Injectionestramustinecarboplatin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00016913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00016913.